Eli Lilly and Co.

Lilly shares rise on possibility for Alzheimer’s drug

December 7, 2011
Bloomberg News
Eli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s experimental Alzheimer’s drug could double the share price.
More

Takeda, Lilly may face thousands of suits over Actos claims

December 1, 2011
Bloomberg News
Takeda Pharmaceutical Co. and marketing co-partner Eli Lilly and Co. may face as many as 10,000 lawsuits in U.S. courts over allegations that their Actos diabetes drug causes bladder cancer.
More

Drugmakers, pharmacists at odds

November 28, 2011
J.K. Wall
Indianapolis-based Eli Lilly and Co. recently rejected CVS Caremark’s demands for big price discounts on its insulins, leading CVS to kick Lilly’s insulins off its list of recommended drugs.
More

Lilly committed to China despite IP woes

November 21, 2011
J.K. Wall
Indianapolis-based Eli Lilly and Co. is one of several Western pharmaceutical firms that see China as a linchpin of growth in coming years, due to patent expirations and a slowdown in government reimbursements for prescription medicines in the U.S. and European markets.
More

Potential Lilly drug doubles good cholesterol

November 15, 2011
Bloomberg News
Eli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck & Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.
More

Potential Effient rival shows promise in study

November 14, 2011
Bloomberg News
A study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could give the companies entry to a $1 billion-plus market where Eli Lilly already competes.
More

Lilly files suit over flea medication sales from Australia

November 11, 2011
Scott Olson
The Indianapolis-based pharmaceutical firm claims an Australian veterinary clinic is infringing on its Comfortis flea medication's trademark by reselling it to U.S. consumers online.
More

Lilly, Amylin agree to end diabetes partnership

November 8, 2011
Bloomberg News, Associated Press
Amylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to end a decade-long diabetes partnership to resolve litigation. Amylin will make an upfront payment of $250 million to Lilly and future revenue-sharing payments of $1.2 billion plus interest.
More

Lilly, Bristol-Myers approved to market wider Erbitux use

November 7, 2011
Bloomberg News
Eli Lilly and Co. and Bristol-Myers Squibb Co. won U.S. approval to expand marketing of the cancer drug Erbitux for late-stage head and neck tumors.
More

Drug shortages hit Lilly, Endocyte

November 7, 2011
J.K. Wall
The nation’s shortage of certain drugs is threatening to affect research trials being conducted by Eli Lilly and Co. and Endocyte Inc.
More

Lilly hid Zyprexa's diabetes risks, family’s lawyer argues

November 2, 2011
Bloomberg News
Eli Lilly and Co. hid the diabetes risks of Zyprexa to protect sales, a lawyer for the family of a 20-year-old patient who died while taking the medicine told a jury in the first case to go to trial over the drug. The attorney asked jurors to award the family $40 million in compensatory damages.
More

Lilly loses British Supreme Court ruling over gene patent

November 2, 2011
Bloomberg News
The British Supreme Court ruled in favor of Human Genome Sciences Inc. in its dispute with Eli Lilly and Co. over the validity of a patent for a gene sequence that could be used to treat people with immune diseases.
More

Q&A

October 31, 2011
J.K. Wall
As an Eli Lilly and Co. lobbyist in Washington, D.C., Jay Bonitt is hoping the Congressional “super committee” charged with trimming the federal budget doesn’t turn to the Medicare prescription drug program, known as Part D, to do so. Bonitt, Lilly's vice president of federal affairs, said the program is under budget and helps spur drugmakers to further innovation.
More

Lilly fights view that fate hinges on Alzheimer's drugRestricted Content

October 29, 2011
Greg Andrews
Analysts have eyes on trial data for drug that could be a game-changer for the company.
More

Lilly wins European approval for new use of Alimta

October 28, 2011
J.K. Wall
Indianapolis-based drugmaker can now market lung cancer drug as a continuation maintenance therapy, potentially boosting sales after recent loss of patent on bestseller Zyprexa.
More

Zyprexa era comes to an end for LillyRestricted Content

October 27, 2011
 IBJ Staff
On Oct. 24, the U.S. Food and Drug Administration approved the first generic versions of Eli Lilly and Co.’s best-seller, ending 15 years of highly lucrative sales.
More

FDA approves first generic versions of Zyprexa

October 24, 2011
 IBJ Staff and Associated Press
Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, which posted sales of $5.7 billion last year for Indianapolis-based drugmaker Eli Lilly and Co Inc.
More

Lilly: Vendors key after Zyprexa patent loss

October 24, 2011
J.K. Wall
Lilly's patent-loss challenges—the biggest of which takes effect today—will force the company to rely even more on its 1,300 Indiana vendors.
More

Profit falls at Lilly but meets Wall Street expectations

October 20, 2011
J.K. Wall
The Indianapolis-based drugmaker earned $1.24 billion in the three months ended Sept. 30, down 5 percent from the same quarter a year ago, even as revenue surged 9 percent.
More

Lilly diabetes drug wins approval for expanded use

October 19, 2011
Bloomberg News
Eli Lilly and Co. and Amylin Pharmaceuticals Inc.’s Byetta has received expanded approval for use with the world’s top-selling insulin to treat Type 2 diabetes.
More

Lilly announces replacements for two retiring executives

October 11, 2011
J.K. Wall
Bryce Carmine, president of Lilly’s bio-medicines division, and Frank Deane, president of Lilly’s global manufacturing operations, both will retire on Dec. 31.
More

Lilly gets dinged for job cuts

October 10, 2011
J.K. Wall
Eli Lilly and Co. got called out in a recent report on companies that took advantage of the 2004 tax holiday on foreign profits and have since slashed jobs.
More

Lilly slashes water use, reduces waste outputRestricted Content

October 8, 2011
 IBJ Staff
By 2013, Lilly hopes to reduce water intake another 5 percent, while reducing the amount of waste sent to landfills an additional 20 percent.
More

FDA approves Cialis for enlarged prostate

October 7, 2011
Cialis, Lilly's blockbuster erectile dysfunction drug, now can be taken to treat enlarged prostate. FDA approval means men who suffer from both disorders can take one medication.
More

Lilly CEO says he's not interested in Pfizer animal unit

October 5, 2011
Bloomberg News
Drugmaker Eli Lilly and Co. doesn’t plan to buy Pfizer Inc.’s $3.58 billion animal-health business, CEO John Lechleiter said Wednesday.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Apologies for the wall of text. I promise I had this nicely formatted in paragraphs in Notepad before pasting here.

  2. I believe that is incorrect Sir, the people's tax-dollars are NOT paying for the companies investment. Without the tax-break the company would be paying an ADDITIONAL $11.1 million in taxes ON TOP of their $22.5 Million investment (Building + IT), for a total of $33.6M or a 50% tax rate. Also, the article does not specify what the total taxes were BEFORE the break. Usually such a corporate tax-break is a 'discount' not a 100% wavier of tax obligations. For sake of example lets say the original taxes added up to $30M over 10 years. $12.5M, New Building $10.0M, IT infrastructure $30.0M, Total Taxes (Example Number) == $52.5M ININ's Cost - $1.8M /10 years, Tax Break (Building) - $0.75M /10 years, Tax Break (IT Infrastructure) - $8.6M /2 years, Tax Breaks (against Hiring Commitment: 430 new jobs /2 years) == 11.5M Possible tax breaks. ININ TOTAL COST: $41M Even if you assume a 100% break, change the '30.0M' to '11.5M' and you can see the Company will be paying a minimum of $22.5, out-of-pocket for their capital-investment - NOT the tax-payers. Also note, much of this money is being spent locally in Indiana and it is creating 430 jobs in your city. I admit I'm a little unclear which tax-breaks are allocated to exactly which expenses. Clearly this is all oversimplified but I think we have both made our points! :) Sorry for the long post.

  3. Clearly, there is a lack of a basic understanding of economics. It is not up to the company to decide what to pay its workers. If companies were able to decide how much to pay their workers then why wouldn't they pay everyone minimum wage? Why choose to pay $10 or $14 when they could pay $7? The answer is that companies DO NOT decide how much to pay workers. It is the market that dictates what a worker is worth and how much they should get paid. If Lowe's chooses to pay a call center worker $7 an hour it will not be able to hire anyone for the job, because all those people will work for someone else paying the market rate of $10-$14 an hour. This forces Lowes to pay its workers that much. Not because it wants to pay them that much out of the goodness of their heart, but because it has to pay them that much in order to stay competitive and attract good workers.

  4. GOOD DAY to you I am Mr Howell Henry, a Reputable, Legitimate & an accredited money Lender. I loan money out to individuals in need of financial assistance. Do you have a bad credit or are you in need of money to pay bills? i want to use this medium to inform you that i render reliable beneficiary assistance as I'll be glad to offer you a loan at 2% interest rate to reliable individuals. Services Rendered include: *Refinance *Home Improvement *Inventor Loans *Auto Loans *Debt Consolidation *Horse Loans *Line of Credit *Second Mortgage *Business Loans *Personal Loans *International Loans. Please write back if interested. Upon Response, you'll be mailed a Loan application form to fill. (No social security and no credit check, 100% Guaranteed!) I Look forward permitting me to be of service to you. You can contact me via e-mail howellhenryloanfirm@gmail.com Yours Sincerely MR Howell Henry(MD)

  5. It is sad to see these races not have a full attendance. The Indy Car races are so much more exciting than Nascar. It seems to me the commenters here are still a little upset with Tony George from a move he made 20 years ago. It was his decision to make, not yours. He lost his position over it. But I believe the problem in all pro sports is the escalating price of admission. In todays economy, people have to pay much more for food and gas. The average fan cannot attend many events anymore. It's gotten priced out of most peoples budgets.

ADVERTISEMENT